Wannan shafin yana aiwatar da ayyuka na asali kuma bai shirya don amfanin marasa lafiya ba tukuna.
Wannan shafin yana aiwatar da ayyuka na asali kuma bai shirya don amfanin marasa lafiya ba tukuna.
Kamuwar hanta mai tsanani da kwayar cutar hepatitis B ke haifarwa, wadda ake kamuwa ta hanyar jini da ruwan jiki. Tana iya haifar da ciwon hanta na yau da kullun, cirrhosis, da kansar hanta.
Kamuwar hanta mai tsanani da kwayar cutar hepatitis B ke haifarwa, wadda ake kamuwa ta hanyar jini da ruwan jiki. Tana iya haifar da ciwon hanta na yau da kullun, cirrhosis, da kansar hanta.
Ma'aikatan kiwon lafiya, matafiya zuwa yankunan da ake samun cutar, jarirai, mutane masu abokan zama da yawa.
Pregnancy: Safe and recommended when indicated.
Hepatitis B vaccine is a recombinant (non-infectious) vaccine and is safe during all trimesters of pregnancy.
WHO and CDC recommend vaccination for pregnant women at risk of HBV infection.
Neonatal hepatitis B prevention: if the mother is HBsAg-positive, the neonate must receive HBIG + first vaccine dose within 12 hours of birth.
No teratogenic or fetotoxic effects observed in extensive post-marketing surveillance.
Standard 3-dose schedule can be initiated or continued during pregnancy.
Breastfeeding: Safe — no restrictions.
Hepatitis B vaccine is a recombinant, non-infectious vaccine and is completely safe during breastfeeding. No vaccine components are excreted in breast milk in clinically significant amounts. No modification to breastfeeding or vaccination schedule is required.
Pediatric use:
Birth dose recommended by WHO within 24 hours of birth (universal).
Pediatric dose: 5–10 µg depending on formulation (half the adult dose).
Schedule: birth, 1, 6 months (or as part of hexavalent combination vaccines).
Preterm infants (<2000 g): may have reduced response to birth dose — repeat 3-dose series starting at 1 month of chronological age.
Anti-HBs testing 1–2 months after series completion recommended for infants born to HBsAg-positive mothers.
Seroprotection rate (anti-HBs ≥10 mIU/mL): >95% in healthy infants after complete series.
Geriatric use:
Immune response decreases with age: seroprotection rates are 75–90% in adults >40 years and may be lower in ≥60 years.
Higher dose (40 µg) or additional doses may be required for elderly non-responders.
Check anti-HBs 1–2 months after series completion to verify seroprotection (≥10 mIU/mL).
Heplisav-B (adjuvanted, 2-dose schedule) achieves higher seroprotection rates in older adults compared to standard formulations.
No dose adjustment for standard formulations in the absence of other risk factors (renal insufficiency, immunosuppression).
| Allura | Kwanaki daga na baya | Kewayon shekaru |
|---|---|---|
| Allura 1 | — | 18 shekaru+ |
| Allura 2 | 30d | — |
Kun san allurar rigakafin da kuke bukata? Da kyau. Ba ku sani ba? Ku gaya mana inda kuke tafiya — za mu nemo allurar da ta dace da asibiti. Kyauta, ba tare da wani hakki ba.
Abun ciki a wannan shafin don bayani da ilimi ne kawai. Ba ya zama shawarar likita, gano cuta, ko shawarwarin magani ba. Idan kuna da damuwar lafiya, tuntuɓi ƙwararren ma’aikacin lafiya. Medova ba mai ba da sabis na likitanci ba ne.
Cikakkun sharuɗɗan amfaniCikakken jerin abubuwa daga makonni 8 kafin tashi har zuwa ranar tafiya: allurar rigakafi, magunguna, kayan lafiya, inshora, da lambobin gaggawa.
Jerin dubawa da hanya: inda za ka je, lokaci, haɗari da lokacin ganin likita.